Dorian Therapeutics
Organization Description
Dorian Therapeutics is a company developing “senoblockers,” a new class of therapeutics intended to to neutralize the harmful effects of senescent cells while reactivating stem cells by targeting the epigenetic regulators of both processes. Based on a patented technology developed at Stanford University, Dorian claimed that their technology inhibited aging process and rejuvenated T-cells ex vivo, increasing their function, fitness, and persistence and enabling tumor regression.
In May 2025, Dorian cofounder and CEO Maddalena Adorno announced that they had been acquired by Altos Labs; no details were included. The acquisition was also announced on their website, which is inactive as of August 2025, as is their LinkedIn page.
Team
